Skip to product information
1 of 1

Ebola virus Glycoprotein/GP RBD His Tag Protein, Ebola virus-AHX24649

Ebola virus Glycoprotein/GP RBD His Tag Protein, Ebola virus-AHX24649

Catalog Number: UA030098 Brand: UA BIOSCIENCE
Price:
Regular price $390.00 SGD
Regular price Sale price $390.00 SGD
Size:
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Species Ebola virus
Synonyms Glycoprotein/GP
Accession AHX24649
Amino Acid Sequence

Met1-Phe308 with His Tag at the C-Terminus

Expression System HEK293
Molecular Weight 55-72kDa (Reducing)
Purity >95% by SDS-PAGE
Conjugation Unconjugated
Tag His Tag
Physical Appearance Lyophilized Powder
Storage Buffer

PBS, PH7.4, 5% trehalose

Reconstitution Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
Stability & Storage

· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.

Reference

1.Pinski AN, Messaoudi I. Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity. Curr Opin Virol. 2021 Dec;51:179-189.
2.Merritt S, Halbrook M, Kompany JP, Chandrasekaran P, Smith OA, Hoff NA, Tambu M, Martin SA, Wong TA, Jarra A, Barrall AL, Musene K, Beya M, Orr R, Myers T, MacGill T, Hensley LE, Muyembe-Tamfum JJ, Kaba D, Berry IM, Mbala-Kingebeni P, Lehrer AT, Rimoin AW. Comparison of EBOV GP IgG antibody reactivity: Results from two immunoassays in the Democratic Republic of the Congo. J Virol Methods. 2025 Jul;336:115154.

Background

The Ebola virus glycoprotein (GP) is a key protein responsible for its pathogenicity. As a class I fusion protein, it forms a trimeric structure on the viral surface composed of GP1 and GP2 subunits linked by disulfide bonds. During viral entry, the receptor-binding domain of GP1 interacts with various host cell receptors (such as TIM-1 and NPC1), while GP2 mediates the fusion between the viral and host cell membranes, facilitating the release of the viral genome into the cytoplasm.Beyond mediating viral entry, GP exerts multiple complex pathogenic effects during later stages of infection. It downregulates the expression of host cell surface adhesion molecules, such as integrins, disrupting intercellular connections and compromising vascular integrity, which may contribute to the hemorrhagic symptoms characteristic of Ebola virus disease. In terms of immune regulation, GP interacts with host TLR4, activating immune cells and triggering a severe cytokine storm, while simultaneously inducing bystander death of T lymphocytes, thereby impairing adaptive immune responses. Additionally, GP counteracts host antiviral factors like BST2/tetherin and acts as a "molecular decoy" to neutralize antibodies, enabling effective immune evasion. These multifunctional properties collectively establish GP as a central target for studying Ebola virus pathogenesis and designing vaccines.

Picture

SDS-PAGE

1μg (R: reducing condition, N:non-reducing condition).